Global Animal Drug Compounding Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Animal Drug Compounding Market Research Report 2024
Compounding is the mixing of drugs to fit the unique needs of a patient. AHI and AVMA define it as “customized manipulation of an approved drug or drugs by a veterinarian, or by a pharmacist upon the prescription of a veterinarian, to meet the needs of a particular patient.
According to Mr Accuracy reports’s new survey, global Animal Drug Compounding market is projected to reach US$ 1286.2 million in 2034, increasing from US$ 818.9 million in 2024, with the CAGR of 6.2% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Animal Drug Compounding market research.
Animal drug shortages are becoming more common and this is unfortunately predicted to worsen in the years ahead, as per official reports published by veterinarians. This shortage encourages the use of widely available compounded drugs to treat a number of animal diseases. A few critical animal drug shortages highlighted by the U.S. FDA are Flunixine Injectable, 35% Perox-Aid, and Epinephrine. To make medical therapy suitable for animal requirements, compounded drugs with the desired active ingredients are unavailable. For e.g., no FDA approved drug for treating megacolon in cats is currently available in the animal drug compounding market. The only safe and effective therapy to treat chronic cat constipation was removed from the U.S. nearly two decades ago. That is why compounding drugs are the only option for veterinarians to treat animals that need pro-kinetic drug therapy.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Animal Drug Compounding market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Triangle Compounding Pharmacy
Lorraine's Pharmacy
Medisca
Diamondback Drugs
ESSENTIAL PHARMACY COMPOUNDING VET
Segment by Type
Anti-Infective Agents
Hormones and Substitutes
Anti-Inflammatory Agents
Others
Veterinary Hospitals
Veterinary Clinics
Veterinary Diagnostic Centers
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Animal Drug Compounding report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Animal Drug Compounding market is projected to reach US$ 1286.2 million in 2034, increasing from US$ 818.9 million in 2024, with the CAGR of 6.2% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Animal Drug Compounding market research.
Animal drug shortages are becoming more common and this is unfortunately predicted to worsen in the years ahead, as per official reports published by veterinarians. This shortage encourages the use of widely available compounded drugs to treat a number of animal diseases. A few critical animal drug shortages highlighted by the U.S. FDA are Flunixine Injectable, 35% Perox-Aid, and Epinephrine. To make medical therapy suitable for animal requirements, compounded drugs with the desired active ingredients are unavailable. For e.g., no FDA approved drug for treating megacolon in cats is currently available in the animal drug compounding market. The only safe and effective therapy to treat chronic cat constipation was removed from the U.S. nearly two decades ago. That is why compounding drugs are the only option for veterinarians to treat animals that need pro-kinetic drug therapy.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Animal Drug Compounding market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Triangle Compounding Pharmacy
Lorraine's Pharmacy
Medisca
Diamondback Drugs
ESSENTIAL PHARMACY COMPOUNDING VET
Segment by Type
Anti-Infective Agents
Hormones and Substitutes
Anti-Inflammatory Agents
Others
Segment by Application
Veterinary Hospitals
Veterinary Clinics
Veterinary Diagnostic Centers
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Animal Drug Compounding report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source